For speculators intrigued by discounts among blue-chip giants, healthcare juggernaut AbbVie (ABBV) is well worth ...

AbbVie Inc. closed 8.64% below its 52-week high of $244.81, which the company achieved on October 1st.

AbbVie’s ABBV stock slipped below its 50-day simple moving average (SMA) late last week. The stock has also declined by ...

AbbVie (ABBV) just caught a fresh tailwind after HSBC bumped the stock to a Buy, a move that comes on top of strong quarterly ...

Discover why AbbVie (ABBV) is rated Strong Buy, with robust 2025 growth, diversified revenues, and attractive valuation.

AbbVie’s latest narrative update leaves its fair value estimate steady at roughly $243.55 per share, even as small tweaks to the model reflect a slightly higher discount rate, a touch softer revenue ...

AbbVie’s ABBV stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since early July. The 50-day moving average is a short-term indicator, while the 200-day moving average ...

AbbVie’s solid stock performance is driven by rising investor optimism as the company has successfully navigated the loss of exclusivity (“LOE”) of its blockbuster drug, Humira, which once generated ...

We recently published a list of ChatGPT Stock Advice: Top 12 Stock Recommendations. In this article, we will take a look at where AbbVie Inc. (NYSE:ABBV) stands against other top stock recommendations ...

The Pharmaceutical Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar. This drugmaker has a strong ...